Kristoffer Rohrberg

All papers authored by Kristoffer Rohrberg

This paper was not found in any repository, but could be made available legally by the author.

2024 Solange Peters

, Eric Angevin

, Teresa Alonso-Gordoa

, Kristoffer Rohrberg

, Ignacio Melero

, Begoña Mellado

, Jose-Luis Perez-Gracia

, Josep Tabernero

, Celine Adessi

, Christophe Boetsch

, Carl Watson

, Joseph Dal Porto

, David Dejardin

, Christopher Del Nagro

, Christopher DelNagro and 11 other authors

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Upload

2023 Ignacio Melero

, Tamara Tanos

, Mariana and Sanmamed Miguel F. Bustamante

, Miguel F. Sanmamed, Emiliano Calvo

, Irene and Moreno Victor Moreno

, Victor Moreno

, Tatiana Hernandez

, Maria Martinez Garcia

, Alejo Rodriguez-Vida

, Josep Tabernero

, Analia Azaro

, Mariano Ponz-Sarvisé

, Iben Spanggaard

, Kristoffer Rohrberg

and 10 other authors

A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

, Sant P. Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P. Steinbach, Michael C. Burger and 16 other authors

Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Supplementary Data Figure S3 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Upload

Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Figure S1 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Upload

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Figure S2 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Upload

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

Supplementary Figure S3 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg

Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Table S2 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Upload

Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Table S1 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Upload

Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Data from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Upload

2021 Antje Wick, Oliver Bähr, Martin Schuler

, Kristoffer Rohrberg

, Sant P. Chawla, Filip Janku

, David Schiff

, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz

, Masafumi Ikeda

, Yuichi Ando

, Wolfgang Wick

, Joachim P. Steinbach, Michael C. Burger and 16 other authors

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Upload

This paper is made freely available by the publisher.

Kristoffer S. Rohrberg

, Ulrik Lassen

Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology

Download from link.springer.com

2020 Vinicius Araujo B. de Lima, Annie Borch

, Morten Hansen, Arianna Draghi

, Iben Spanggaard, Kristoffer Rohrberg

, Sine Reker Hadrup, Ulrik Lassen

, Inge Marie Svane

Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome

Upload

2018 Ida Viller Tuxen, Kristoffer Staal Rohrberg

, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen

Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Download from aacrjournals.org

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Kristoffer Rohrberg